FindTrial
Sign In

Gemcitabine 2 g Powder for Solution for Infusion

DRUG3 trials

Sponsors

Janssen Cilag International, Karyopharm Therapeutics Inc., Regeneron Pharmaceuticals Inc.

Conditions

Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or FusionsNon-small Cell Lung CancerRelapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

Phase 2

A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions
CompletedCTIS2023-510306-40-00
Janssen Cilag InternationalCohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions
Start: 2020-08-11End: 2025-02-27Target: 6Updated: 2025-01-22
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine- Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL).
Active, not recruitingCTIS2024-513616-95-00
Karyopharm Therapeutics Inc.Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
Start: 2020-12-22Target: 60Updated: 2025-10-02

Phase 3

A Global, Randomized, Phase 3, Open-Label Study of REGN2810 (Anti-PD-1 Antibody) versus Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic PD-L1 + Non-Small Cell Lung Cancer
CompletedCTIS2024-515052-20-00
Regeneron Pharmaceuticals Inc.Non-small Cell Lung Cancer
Start: 2017-09-20End: 2025-04-18Target: 68Updated: 2024-12-10